Article
Hematology
Byung-Sik Cho, Gi-June Min, Silvia Park, Sung-Soo Park, Seung-Hwan Shin, Seung-Ah Yahng, Young-Woo Jeon, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Myungshin Kim, Yonggoo Kim, Hee-Je Kim
Summary: This prospective study demonstrated the non-inferiority of Haplo-HSCT to MUD-HSCT for AML in remission, and validated the role of WT1 quantification as an MRD marker. Both groups had similar outcomes in terms of overall and disease-free survival, relapse, non-relapse mortality, and GVHD-free/relapse-free survival.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Curtis Marcoux, David Marin, Jeremy Ramdial, Gheath AlAtrash, Amin M. Alousi, Betul Oran, Partow Kebriaei, Uday R. Popat, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta
Summary: Optimal donor selection is crucial in allogeneic hematopoietic cell transplantation, and this study compares the outcomes of patients who received transplants from younger haploidentical donors or older matched unrelated donors. The use of younger haploidentical donors was associated with improved survival and lower rates of GVHD compared to older MUDs. These findings support the use of younger haploidentical donors with post-transplant cyclophosphamide in patients with MDS or AML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Yoshimitsu Shimomura, Tomotaka Sobue, Shigeki Hirabayashi, Tadakazu Kondo, Shohei Mizuno, Junya Kanda, Takahiro Fujino, Keisuke Kataoka, Naoyuki Uchida, Tetsuya Eto, Shigesaburo Miyakoshi, Masatsugu Tanaka, Toshiro Kawakita, Hisayuki Yokoyama, Noriko Doki, Kaito Harada, Atsushi Wake, Shuichi Ota, Satoru Takada, Satoshi Takahashi, Takafumi Kimura, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada
Summary: CBT transplantation resulted in better 5-year progression-free survival compared to MRDT in patients with non-remission R/R AML, mainly due to a lower relapse rate and a higher non-relapse mortality rate in the CBT group.
Article
Biochemistry & Molecular Biology
Irtiza N. Sheikh, Shaikha Alqahtani, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Kris M. Mahadeo, Uday Popat, Elizabeth J. Shpall, Sajad Khazal
Summary: Post-transplant cyclophosphamide (PTCy) is a potentially safe and effective GVHD prophylaxis strategy in pediatric HSCT recipients, showing reduced mortality and unaffected engraftment and immune reconstitution.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Article
Cell & Tissue Engineering
Guangyu Sun, Baolin Tang, Kaidi Song, Yue Wu, Meijuan Tu, Xiang Wan, Wen Yao, Liangquan Geng, Ping Qiang, Xiaoyu Zhu
Summary: This study compared the outcomes of UCBT and MST in the treatment of adult B-ALL patients. The results showed that UCBT had slower hematopoietic recovery but lower incidence of extensive cGVHD. The NRM, relapse, DFS, and GRFS were comparable between MST and UCBT recipients, but UCBT showed better OS for patients with long-term survival.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Helene Labussiere-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jurgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of CBT and single-allele-mismatched MMUD allo-HCT with PTCy in acute myeloid leukemia. The results showed that CBT was associated with higher incidence of graft failure and non-relapse mortality compared to MMUD, leading to lower leukemia-free survival, overall survival, and GVHD-free, relapse-free survival. In conclusion, MMUD allo-HCT with PTCy may be a preferred choice over CBT for patients without a fully matched donor.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Hematology
Yue Lu, Yan-Li Zhao, Jian-Ping Zhang, Min Xiong, Xing-Yu Cao, De-Yan Liu, Rui-Juan Sun, Zhi-Jie Wei, Jia-Rui Zhou, Dao-Pei Lu
Summary: This study compared the outcomes of different donor sources in AML patients undergoing transplantation and concluded that HID-HSCT had similar survival and relapse rates compared to MUD and MSD-HSCT, indicating that HID is a valid option.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Riccardo Masetti, Edoardo Muratore, Davide Gori, Arcangelo Prete, Franco Locatelli
Summary: The selection of allo-HSCT for pediatric patients with AML in CR1 is still debated. This meta-analysis found that allo-HSCT improved overall survival and disease-free survival compared to chemotherapy in high-risk pediatric AML patients in CR1, but with an increased relapse rate. Sensitivity analysis confirmed the benefit of allo-HSCT on overall survival. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.
ANNALS OF HEMATOLOGY
(2022)
Article
Hematology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Immunology
Long Su, Ming-Hui Fang, Jun Zou, Su-Jun Gao, Xiao-Yi Gu, Xian-Di Meng, Xue Wang, Zheng Hu, Yong-Guang Yang
Summary: The study showed that posttransplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the BM, enhanced GVL effects, and promoted donor hematopoietic engraftment. Additionally, posttransplant treatment with AMD3100 had no detectable deleterious effect related to GVHD.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Oncology
Jaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, Boris Afanasyev, Moiseev Ivan Sergeevich, Emanuele Angelucci, Nicolaus Kroger, Yener Koc, Fabio Ciceri, J. L. Diez-Martin, Mutlu Arat, Simona Sica, Montserrat Rovira, Mahmoud Aljurf, Johanna Tischer, Bipin Savani, Annalisa Ruggeri, Arnon Nagler, Mohamad Mohty
Summary: In allogeneic hematopoietic stem cell transplantation using PTCy for GVHD prophylaxis in acute lymphoblastic leukemia patients, the donor type did not significantly impact transplant outcomes, with similar overall survival and relapse rates observed across different donor types.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Hematology
Mariana Pinto Pereira, Mats Remberger, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H. Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic
Summary: The choice between an older matched sibling donor (MSD) and a younger matched unrelated donor (MUD) remains debated in allogeneic hematopoietic cell transplantation (HCT). In this study, researchers compared outcomes of patients who received grafts from MSDs age >60 years and MUDs age <30 years for AML and MDS, and found no significant differences in most measures.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Oncology
Shigeki Hirabayashi, Ryuji Uozumi, Tadakazu Kondo, Yasuyuki Arai, Takahito Kawata, Naoyuki Uchida, Atsushi Marumo, Kazuhiro Ikegame, Takahiro Fukuda, Tetsuya Eto, Masatsugu Tanaka, Atsushi Wake, Junya Kanda, Takafumi Kimura, Ken Tabuchi, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada, Shingo Yano
Summary: This study aimed to develop and validate nomograms and a web application to predict the overall survival of patients with non-complete remission AML undergoing allo-HCT. Significant prognostic factors among patients undergoing allo-HCT included age, performance status, percentage of peripheral blasts, cytogenetic risk, chemotherapy response, and number of transplantations. The effectiveness of multi-drug conditioning regimens in patients undergoing CBT was indicated in the study.
Letter
Oncology
Anna B. Halpern, Megan Othus, Genevieve Alcorn, Zahra Ali, Kelsey-Leigh A. Garcia, Mary-Elizabeth M. Percival, Sioban B. Keel, Ryan D. Cassaday, Pamela S. Becker, Elihu H. Estey, Roland B. Walter
Letter
Oncology
Noam E. Kopmar, Megan Othus, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Bart L. Scott, Paul C. Hendrie, Roland B. Walter, Pamela S. Becker, Elihu H. Estey, Mary-Elizabeth M. Percival
Article
Oncology
Anna B. Halpern, Megan Othus, Nicholas P. Howard, Paul C. Hendrie, Mary-Elizabeth M. Percival, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, Roland B. Walter
Summary: The study found that early hospital discharge (EHD) care strategy following intensive acute myeloid leukemia (AML)-like chemotherapy is safe, but EHD patients had higher rates of gram-positive bacteremias. Improvements in catheter management may help increase the safety of this care approach.
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Corentin Orvain, Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodriguez-Arboli, Brent L. Wood, Megan Othus, Frederick R. Appelbaum, Roland B. Walter
Summary: Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent prognostic factor for acute myeloid leukemia (AML) patients. The combination of residual cytogenetic abnormalities and MRD testing by multiparameter flow cytometry (MFC) improves risk assessment before HCT and provides complementary prognostic information for post-HCT outcomes in patients with cytogenetically abnormal AML undergoing allogeneic HCT.
Letter
Oncology
Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham, Robert K. Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Nigel Russell, Kathleen F. Kerr, Roland B. Walter, Mike Dennis
LEUKEMIA & LYMPHOMA
(2023)
Meeting Abstract
Hematology
Harry P. Erba, Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, Stephane De Botton, Maria R. Baer, Gary J. Schiller, Roland B. Walter, Marina Kremyanskaya, Kristen M. Pettit, Stephen A. Strickland, Blake Tomkinson, Marilyn Tabachri, Mollie Leoni, Stephen Dale, Eunice S. Wang
Meeting Abstract
Hematology
John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Roland B. Walter, Mary-Elizabeth M. Percival
Article
Biophysics
Roland B. Walter, Brenda M. Sandmaier, Megan Othus, Corentin Orvain, Eduardo Rodriguez-Arboli, Masumi U. Oshima, Gary Schoch, Chris Davis, H. Joachim Deeg, Rainer Storb
Summary: Reduced intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning regimens are viable options for allogeneic hematopoietic cell transplantation (HCT) in AML patients. However, the relative efficacies and toxicities of these regimens are not well-defined. This study compared outcomes between RIC and NMA HCT patients and found no significant differences in relapse risk, relapse-free survival, overall survival, and non-relapse mortality. These findings suggest that the choice between RIC and NMA conditioning may not significantly impact outcomes in AML patients undergoing allografting.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Gabrielle Paras, Megan Othus, Kelda Schonhoff, Carole Shaw, Mohamed Sorror, Anna B. Halpern, Jacob Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Letter
Oncology
Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Corentin Orvain, Eduardo Rodriguez-Arboli, Megan Othus, Brenda M. Sandmaier, H. Joachim Deeg, Frederick R. Appelbaum, Roland B. Walter
Summary: This study retrospectively analyzed 739 patients with de novo AML, 125 with antecedent hematologic disorder (AHD)/AML, and 115 with therapy-related AML who received allografts while in first or second remission. The results showed that relative to patients with de novo AML, relapse rates were similar for patients with AHD and therapy-related AML after multivariable adjustment, as were relapse-free survival and overall survival. Non-relapse mortality was higher for AHD AML. These findings suggest that the clinical history by itself has limited prognostic value for AML patients undergoing allografting.
Editorial Material
Oncology
Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Roland Bruno Walter, Adriano Venditti, Francesco Buccisano
Article
Oncology
Michelle Y. Y. Zhang, Megan Othus, Carole Shaw, Kelda G. G. Schonhoff, Anna B. B. Halpern, Jacob Appelbaum, Paul C. C. Hendrie, Roland B. B. Walter, Elihu H. H. Estey, Mary-Elizabeth M. Percival
Summary: Patients with acute myeloid leukemia (AML) who have previously received hypomethylating agents (HMA) have a poor prognosis. High intensity induction chemotherapy may improve outcomes in these patients.
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Noam E. Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B. Halpern, Roland B. Walter, Bart L. Scott, Jacob Appelbaum, Paul C. Hendrie, Elihu H. Estey, Mary-Elizabeth M. Percival
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Lauren Shih, Megan Othus, Kelda Schonhoff, Carole Shaw, Jacob Appelbaum, Anna B. Halpern, Pamela S. Becker, Roland B. Walter, Elihu Estey, Mary-Elizabeth Percival